文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 临床医学 > Are the adverse effects of glitazones
侵权投诉

Are the adverse effects of glitazones

Adverse side-effects of the glitazones have been frequently reported in both clinical and animal studies, especially with rosiglitazone (RGZ) and pioglitazone (PGZ), including congestive heart failure, osteoporosis, weight gain, oedema and anaemia.

Testing of hypothesis

Clinical studies are needed to investigate the endocrineprofiles, including measurements of TT, DHT, SHBG, FTand oestradiol, together with LH and FSH, in both menand women with T2DM before and after RGZ and PGZtreatment in double blind, placebo controlled groups.Also, further studies on T treatment in diabetic menwould further establish if the adverse effects of glitazonescould be ameliorated by androgen therapy. Basic sciencesinvestigations on the inhibition of androgen biosynthesisby glitazones are also warranted.

Implications of the hypothesis

The FDA reports that most PPAR agonists in developmentare non-thiazolidinediones, and though more than 50Innovative New Drug (IND) applications have been filedfor this group of drugs in the last seven years, most devel-opment programs have been terminated, all for safety rea-sons, and none have been approved.

This hypothesis explains the adverse effects of glitazoneson the heart and other organs by reducing androgenaction in directing stem cells differentiation into myo-cytes, vascular endothelium, erythroid stem cells and oste-oblasts, and promoting adipocyte differentiation. Theadverse clinical effects are directly linked to the metabolicactions of these drugs. The higher incidence of side-effectswith RGZ compared with PGZ, may be explained by adetailed study of the mechanism by which glitazonesdown-regulate androgen biosynthesis and molecularmechanism of action, resulting in a state of androgen defi-ciency.

Abbreviations

AR: androgen receptor; CHF: congestive heart failure;CVD: cardiovascular disease; DHT: dihydrotestosterone;FT: free testosterone; IL: interleukin; MI: myocardial inf-arction; PCs: progenitor cells; PGZ: pioglitazone; PPAR:Peroxisome Proliferator-Activated Receptor; RGZ: rosigli-tazone; SHBG: sex hormone binding globulin; T: testo-sterone; TGZ: Troglitazone; TNF-α: tumour necrosisfactor-alpha; T2DM: Type 2 diabetes mellitus; TT: totaltestosterone.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

MC conceived the unifying hypothesis. All authors con-tributed to the initial manuscript, and revisions were car-ried out by MC and AMT. All authors have read andapproved the final manuscript.

Acknowledgements

We thank Prof. Piotr Ponikowski and Prof Waldemar Banasiak of the Car-diology Department, Military Hospital, Wroclaw, Poland, for their advice

on testosterone and CHF, and Mr Stewart McCrea of The Ulster Hospital, Belfast, UK, for the creative artwork in both figures.

References

1.Nissen SE, Wolski K: cardial infarction and death from cardiovascular causes.Effect of rosiglitazone on the risk of myo-2.

Engl J MedHome PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones 2007, 356:2457-2471.

NNP, Komajda M, McMurray JJ: ovascular outcomes – an interim analysis.Rosiglitazone evaluated for cardi-3.357: N Engl J Med 2007,Singh S, Loke YK, Furberg CD: 28-38.

events with rosiglitazone: a meta-analysis.Long-term risk of cardiovascular4.

298: JAMA 2007,Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti1189-1195.

M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E,Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, HeineRJ, Koranyi LScheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith, Laakso M, Mokan M, Norkus A, Pirags V, Podar T,U, Taton J: patients with type 2 diabetes in the PROactive Study (PRO-Secondary prevention of macrovascular events inspective pioglitAzone Clinical Trial In macroVascularEvents): a randomised controlled trial.5.

366: Lancet 2005,Lincoff AM, Wolski K, Nicholls SJ, Nissen SE: 1279-1289.

of cardiovascular events in patients with type 2 diabetes mel-Pioglitazone and risklitus: a meta-analysis of randomized trials.6.298: JAMA 2007,Unger RH: 1180-1188.

7.ment, and prevention.Reinventing type 2 diabetes: pathogenesis, treat-Kapoor D, Malkin CJ, Channer KS, Jones TH: JAMA 2008, 299:1185-1187.

resistance and vascular disease in men.8.2005, Androgens, insulin Clin Endocrinol (Oxf)Choi BG, McLaughlin MA: 63:239-250.

cular Effects of Sex Steroids.Why Men's Hearts Break: Cardiovas-9.2007, Beld AW van den, Bots ML, Janssen JA, Pols HA, Lamberts SW, Grob-36:365-377.

Endocrinol Metab Clin North Ambee DE: 10.elderly men.Endogenous hormones and carotid atherosclerosis inDemirbag R, Yilmaz R, Ulucay A, Unlu D: Am J Epidemiol 2003, 157:25-31.

between thoracic aortic intima media thickness and testo-The inverse relationship11.

sterone level.Muller M, Beld AW van den, Bots ML, Grobbee DE, Lamberts SW, Endocr Res 2005, 31:335-344.

Schouw YT van der: sion of carotid atherosclerosis in elderly men.Endogenous sex hormones and progres-12.

109: Circulation 2004,Hak AE, Witteman JC, de Jong FH, Geerlings MI, Hofman A, Pols HA:2074-2079.

Low levels of endogenous androgens increase the risk ofatherosclerosis in elderly men: the Rotterdam study.13.

Endocrinol Metab J ClinEnglish KM, Mandour O, Steeds RP, Diver MJ, Jones TH, Channer KS: 2002, 87:3632-3639.

Men with coronary artery disease have lower levels of andro-gens than men with normal coronary angiograms.14.JPhillips GB, Pinkernell BH, Jing TY: 2000, 21:890-894.

Eur Heartsteronemia with coronary artery disease in men.The association of hypotesto-15.

ThrombPugh PJ, Channer KS, Parry H, Downes T, Jone TH: 1994, 14:701-706.

Arteriosclertestosterone levels fall acutely following myocardial infarc-Bio-availabletion in men: association with fibrinolytic factors.16.

2002, Jones RD, English KM, Pugh PJ, Morice AH, Jones TH, Channer KS:28:161-173.

Endocr ResPulmonary vasodilatory action of testosterone: evidence of acalcium antagonistic action.17.

39:Jankowska EA, Biel B, Majda J, Szklarska A, Lopuszanska M, Medras M,814-823.

J Cardiovasc Pharmacol 2002,Anker SD, Banasiak W, Poole-Wilson PA, Ponikowski P: deficiency in men with chronic heart failure: prevalence andAnabolicdetrimental impact on survival.18.114: Circulation 2006,Tappler B, Katz M: 1829-1837.

19.

cardiac failure.Pituitary-gonadal dysfunction in low-outputDockery F: Clin Endocrinol (Oxf) 1979, 10:219-226.

cancer leads to an increase in arterial stiffness and hyperin-Testosterone suppression in men with prostatesulinaemia. Clin Sci (Lond) 2003, 104:195-201.

上一页第5页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email